FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178111606> ?p ?o ?g. }

• W3178111606 abstract "Abstract Introduction Antiandrogens are candidates against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to host cell entry inhibition by the suppression of TMPRSS2. Proxalutamide is a nonsteroidal anti-androgen (NSAA) with strong antagonism on androgen receptor (AR) and angiotensin-converting enzyme 2 (ACE2). Efficacy of proxalutamide was previously demonstrated for early COVID-19 outpatients, and also reduction of deaths in hospitalized COVID-19 patients. Whether radiological changes would follow the improvement in clinical outcomes with proxalutamide is not established. The present post-hoc analysis aims to evaluate whether proxalutamide improves lung injury observed through chest computerized tomography (CT) scans. Methods This is a post-hoc analysis of the radiological findings of The Proxa-Rescue AndroCoV Trial with all enrolled patients from the three participating institutions of the city of Manaus, Brazil, that had at least two chest CT scans during hospitalization. The quantification of lung parenchyma involvement was performed by blinded radiologists with expertise in analysis of COVID-19 images. A first chest CT scan was performed upon randomization and a second CT scan was performed approximately five days later, whenever feasible. Improvement rate was the first endpoint, and relative and absolute changes between the first and second CT scans were the second endpoints. Results Of the 395 patients initially evaluated, 77 and 169 patients from the proxalutamide and placebo arms, respectively, were included (n=246). Baseline characteristics and percentage of lung parenchyma affected in the baseline chest CT scan were similar between groups. In the second chest CT scan, the percentage of lungs affected (Median – IQR) was 35.0% (25.0-57.5%) in the proxalutamide group versus 67.5% (50.0-80.0%) in the placebo group (p < 0.001). The absolute and relative change between the second and first chest CT scans (Median – IQR) were -15.0 percent points (p.p.) (−30.0 – 0.0p.p.) and -25.0% (−50.0 – 0.0%) in the proxalutamide group, respectively, and +15.0p.p. (0.0 - +30.0p.p.) and +32.7% (0.0 - +80.0%) in the placebo group, respectively (p < 0.001 for both absolute and relative changes). The improvement rate, i . e ., the percentage of subjects that had improvement from the first to the second CT scan, was 72.3% in the proxalutamide group and 23.1% in the placebo group (p < 0.0001), with an improvement rate ratio (95%CI) of 3.15 (2.32 – 4.28). Conclusion Proxalutamide improves lung opacities in hospitalized COVID-19 patients when compared to placebo. ( NCT04728802 )" @default.
• W3178111606 created "2021-07-19" @default.
• W3178111606 creator A5003924709 @default.
• W3178111606 creator A5005066023 @default.
• W3178111606 creator A5006982060 @default.
• W3178111606 creator A5011256255 @default.
• W3178111606 creator A5023806789 @default.
• W3178111606 creator A5024215230 @default.
• W3178111606 creator A5024851394 @default.
• W3178111606 creator A5025928146 @default.
• W3178111606 creator A5038904017 @default.
• W3178111606 creator A5050659662 @default.
• W3178111606 creator A5054555187 @default.
• W3178111606 creator A5055204006 @default.
• W3178111606 creator A5057950169 @default.
• W3178111606 creator A5063540606 @default.
• W3178111606 creator A5065020857 @default.
• W3178111606 creator A5078195581 @default.
• W3178111606 creator A5078226170 @default.
• W3178111606 creator A5081012733 @default.
• W3178111606 date "2021-07-02" @default.
• W3178111606 modified "2023-10-16" @default.
• W3178111606 title "Proxalutamide Improves Lung Injury in Hospitalized COVID-19 Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial" @default.
• W3178111606 cites W2007239126 @default.
• W3178111606 cites W2035655846 @default.
• W3178111606 cites W3003286392 @default.
• W3178111606 cites W3009875419 @default.
• W3178111606 cites W3009912996 @default.
• W3178111606 cites W3011048075 @default.
• W3178111606 cites W3011414603 @default.
• W3178111606 cites W3015141576 @default.
• W3178111606 cites W3016232369 @default.
• W3178111606 cites W3019336217 @default.
• W3178111606 cites W3025990187 @default.
• W3178111606 cites W3029307542 @default.
• W3178111606 cites W3041371401 @default.
• W3178111606 cites W3108672867 @default.
• W3178111606 cites W3110752337 @default.
• W3178111606 cites W3118433754 @default.
• W3178111606 cites W3129019794 @default.
• W3178111606 cites W3131310855 @default.
• W3178111606 cites W3133959103 @default.
• W3178111606 cites W3134839047 @default.
• W3178111606 cites W3155752458 @default.
• W3178111606 cites W3161718150 @default.
• W3178111606 cites W3174254273 @default.
• W3178111606 cites W3183488957 @default.
• W3178111606 doi "https://doi.org/10.1101/2021.07.01.21259656" @default.
• W3178111606 hasPublicationYear "2021" @default.
• W3178111606 type Work @default.
• W3178111606 sameAs 3178111606 @default.
• W3178111606 citedByCount "4" @default.
• W3178111606 countsByYear W31781116062021 @default.
• W3178111606 countsByYear W31781116062022 @default.
• W3178111606 crossrefType "posted-content" @default.
• W3178111606 hasAuthorship W3178111606A5003924709 @default.
• W3178111606 hasAuthorship W3178111606A5005066023 @default.
• W3178111606 hasAuthorship W3178111606A5006982060 @default.
• W3178111606 hasAuthorship W3178111606A5011256255 @default.
• W3178111606 hasAuthorship W3178111606A5023806789 @default.
• W3178111606 hasAuthorship W3178111606A5024215230 @default.
• W3178111606 hasAuthorship W3178111606A5024851394 @default.
• W3178111606 hasAuthorship W3178111606A5025928146 @default.
• W3178111606 hasAuthorship W3178111606A5038904017 @default.
• W3178111606 hasAuthorship W3178111606A5050659662 @default.
• W3178111606 hasAuthorship W3178111606A5054555187 @default.
• W3178111606 hasAuthorship W3178111606A5055204006 @default.
• W3178111606 hasAuthorship W3178111606A5057950169 @default.
• W3178111606 hasAuthorship W3178111606A5063540606 @default.
• W3178111606 hasAuthorship W3178111606A5065020857 @default.
• W3178111606 hasAuthorship W3178111606A5078195581 @default.
• W3178111606 hasAuthorship W3178111606A5078226170 @default.
• W3178111606 hasAuthorship W3178111606A5081012733 @default.
• W3178111606 hasBestOaLocation W31781116061 @default.
• W3178111606 hasConcept C126322002 @default.
• W3178111606 hasConcept C126838900 @default.
• W3178111606 hasConcept C142724271 @default.
• W3178111606 hasConcept C190892606 @default.
• W3178111606 hasConcept C203092338 @default.
• W3178111606 hasConcept C204787440 @default.
• W3178111606 hasConcept C27081682 @default.
• W3178111606 hasConcept C2777714996 @default.
• W3178111606 hasConcept C535046627 @default.
• W3178111606 hasConcept C67761136 @default.
• W3178111606 hasConcept C71924100 @default.
• W3178111606 hasConceptScore W3178111606C126322002 @default.
• W3178111606 hasConceptScore W3178111606C126838900 @default.
• W3178111606 hasConceptScore W3178111606C142724271 @default.
• W3178111606 hasConceptScore W3178111606C190892606 @default.
• W3178111606 hasConceptScore W3178111606C203092338 @default.
• W3178111606 hasConceptScore W3178111606C204787440 @default.
• W3178111606 hasConceptScore W3178111606C27081682 @default.
• W3178111606 hasConceptScore W3178111606C2777714996 @default.
• W3178111606 hasConceptScore W3178111606C535046627 @default.
• W3178111606 hasConceptScore W3178111606C67761136 @default.
• W3178111606 hasConceptScore W3178111606C71924100 @default.
• W3178111606 hasLocation W31781116061 @default.
• W3178111606 hasOpenAccess W3178111606 @default.
• W3178111606 hasPrimaryLocation W31781116061 @default.
• W3178111606 hasRelatedWork W2559795988 @default.

• next